https://www.selleckchem.com/pr....oducts/h-cys-trt-oh.
For each disease, an independent validation committee reviewed the rEHRs of 100 cases and 100 non-cases in order to adjudicate on the status of the selected patients (true case/ true non-case), blinded with respect to the result of the corresponding algorithm. Algorithm for relapses identification in MS showed a 95% PPV and 100% NPV. Algorithm for mCRPC identification showeda 97% PPV and 99% NPV. The use of rEHRs to conduct an intra-database validation appears to be a valuable tool to estimate the performances of a case-identifying
Like
Comment
Share
